Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of...
- Mechanism
- Curator reviewed
Torcetrapib is an inhibitor of cholesteryl ester-transfer protein (CETP) that increases high-density lipoprotein (HDL) cholesterol levels. The drug increases HDL-cholesterol and apolipoprotein A-I levels and decreases LDL-cholesterol and apolipoprotein B levels. The effect is showed in monotherapy and when administered in combination with statins.
- Primary indication
- Investigated for use/treatment in peripheral vascular disease and hyperlipidemia.Curator reviewed
- Formula / weight
- C26H25F9N2O4 · 600.4733 g/mol (avg)
- Code names
- CP-529,414
Resolves to
CMSGWTNRGKRWGS-NQIIRXRSSA-NSMILESCCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C2=C1C=CC(=C2)C(F)(F)FWhat you can answer from here — as of February 21, 2021
Which drugs share a target with Torcetrapib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account